
PeproMene Bio: A virtual biotech firm in Irvine, CA, innovating novel immune-oncology therapies.
PeproMene Bio, Inc., founded in Irvine, CA, is a clinical-stage biotech company focused on developing innovative immune-oncology therapies. Their core mission is to improve the lives of patients with cancer and immune disorders through novel treatments. The company's flagship product is the BAFF-R CAR-T therapy, which targets the B-cell Activating Factor Receptor (BAFF-R) using a novel antibody. This therapy aims to provide new hope for patients with challenging oncological and immunological conditions.
Notable figures associated with PeproMene Bio include leading scientists and industry experts in the field of immunotherapy. The company has garnered attention from private investors who support its pioneering research. Key achievements include advancing their BAFF-R CAR-T therapy to clinical stages, demonstrating promising potential in preclinical studies. PeproMene Bio's impact lies in its commitment to harnessing cutting-edge science to develop therapies that could significantly alter the treatment landscape for cancer and immune disorders.

Immpact Bio
immpact-bio.com

ManaT Bio
clasptx.com

OncoPep
oncopep.com

INmune Bio
inmunebio.com

Minerva Biotechnologies
minervabio.com

Petri Bio
petribio.com

Therabiol

Dren Bio
drenbio.com

Immune-Onc Therapeutics
immuneonc.com

Epirium Bio
epirium.com

Immunome

Inceptor Bio
inceptor.bio

Bitterroot Bio
brbio.com

Inimmune
inimmune.com

Mongoose Bio
mongoosebio.com
Companies similar to PeproMene Bio include Immpact Bio, ManaT Bio, OncoPep and INmune Bio.
PeproMene Bio was founded in 2016.
PeproMene Bio's headquarters is located in Irvine, CA, US.
PeproMene Bio's most recent funding round was for $4M (USD) in October 2017.
As of Oct 16, 2017, PeproMene Bio has raised a total of $4M (USD).
PeproMene Bio has 5 employees as of Feb 5, 2024.